Study · Randomized controlled trial · n = 50 · 2020

3 results

Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.

van Eyk HJ, Paiman EHM, Bizino MB, IJzermans SL, Kleiburg F, Boers TGW, Rappel EJ, Burakiewicz J, Kan HE, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN

Nutrition, metabolism, and cardiovascular diseases : NMCD13 Dec 2019Cited by 52 (Europe PMC)

PMID32127340DOI10.1016/j.numecd.2019.12.005PepBankPUB-32127340

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced resting energy expenditure after 4 weeks and after 12 weeks.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered the energy the body burns at rest after 4 and 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseResting energy expenditure at weeks 4 and 12
Study
n = 50
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide reduced REE after 4 weeks, which persisted after 12 weeks
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
Report a problemFND-3212734001
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, resting energy expenditure at week 26 tended to be lower with liraglutide than with placebo, but the difference was not significant.
In plain wordsIn adults with type 2 diabetes, energy burned at rest at week 26 tended to be lower with liraglutide than placebo, but not clearly.
Peptide
Liraglutide
Outcome
No significant changeResting energy expenditure at week 26
Study
n = 50
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Change in REE
−52 kcal/day
liraglutide, week 26 vs baseline
Source sentences
Summary
tended to be present after 26 weeks (week 26 vs baseline: liraglutide -52 ± 128 kcal/day; P = 0.071, placebo +44 ± 144 kcal/day; P = 0.153, between group P = 0.057)
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
Report a problemFND-3212734002
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 26 weeks of liraglutide did not change the fat fraction of supraclavicular brown adipose tissue compared with placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide did not change brown fat measures compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeSupraclavicular brown adipose tissue fat fraction
Study
n = 50
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Change in supraclavicular BAT fat fraction
−0.4%
liraglutide
Source sentences
Summary
Treatment with liraglutide for 26 weeks did not decrease the fat fraction in supraclavicular BAT (-0.4 ± 1.7%; P = 0.447) compared to placebo (-0.4 ± 1.4%; P = 0.420; between group P = 0.911).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
Report a problemFND-3212734003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT05419726

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

University of California, Los Angelesn = 201 Feb 2023 to est. 1 Feb 2026

Obesity

Trial page ClinicalTrials.govUpdated 11 May 2025

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial page ClinicalTrials.govUpdated 5 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.